Sheikhlary Sara, Lopez David Humberto, Moghimi Sophia, Sun Bo
Department of Biomedical Engineering, College of Engineering, The University of Arizona, Tucson, AZ 85721, USA.
Department of Pharmacology and Toxicology, College of Pharmacy, The University of Arizona, Tucson, AZ 85721, USA.
Biomolecules. 2024 Apr 21;14(4):503. doi: 10.3390/biom14040503.
Cancer remains one of the global leading causes of death and various vaccines have been developed over the years against it, including cell-based, nucleic acid-based, and viral-based cancer vaccines. Although many vaccines have been effective in in vivo and clinical studies and some have been FDA-approved, there are major limitations to overcome: (1) developing one universal vaccine for a specific cancer is difficult, as tumors with different antigens are different for different individuals, (2) the tumor antigens may be similar to the body's own antigens, and (3) there is the possibility of cancer recurrence. Therefore, developing personalized cancer vaccines with the ability to distinguish between the tumor and the body's antigens is indispensable. This paper provides a comprehensive review of different types of cancer vaccines and highlights important factors necessary for developing efficient cancer vaccines. Moreover, the application of other technologies in cancer therapy is discussed. Finally, several insights and conclusions are presented, such as the possibility of using cold plasma and cancer stem cells in developing future cancer vaccines, to tackle the major limitations in the cancer vaccine developmental process.
癌症仍然是全球主要死因之一,多年来已研发出多种针对癌症的疫苗,包括基于细胞的、基于核酸的和基于病毒的癌症疫苗。尽管许多疫苗在体内和临床研究中已证明有效,且有些已获得美国食品药品监督管理局(FDA)批准,但仍有一些主要限制需要克服:(1)为特定癌症研发一种通用疫苗很困难,因为不同个体带有不同抗原的肿瘤各不相同;(2)肿瘤抗原可能与机体自身抗原相似;(3)存在癌症复发的可能性。因此,研发能够区分肿瘤和机体抗原的个性化癌症疫苗必不可少。本文全面综述了不同类型的癌症疫苗,并强调了开发高效癌症疫苗所需的重要因素。此外,还讨论了其他技术在癌症治疗中的应用。最后,提出了一些见解和结论,例如在未来癌症疫苗开发中使用冷等离子体和癌症干细胞的可能性,以应对癌症疫苗开发过程中的主要限制。